MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,315.00
+75.00 (1.77%)
Jul 18, 2025, 3:30 PM KST
-48.39%
Market Cap147.90B
Revenue (ttm)429.94M
Net Income (ttm)-14.22B
Shares Out34.28M
EPS (ttm)-422.51
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume276,053
Average Volume284,401
Open4,235.00
Previous Close4,240.00
Day's Range4,150.00 - 4,330.00
52-Week Range2,750.00 - 8,440.00
Beta1.11
RSI67.75
Earnings DateAug 8, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Employees 61
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.